Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Alexander Burnett

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentObstetrics & Gynecology, College of Medicine
DivisionOB & GYN Gynecologic Oncology
Address516 Cancer Institute
4104 Outpatient Circle
Mail Slot # 793
Little Rock AR 72205
Phone501-296-1099
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Alexander Burnett, M.D., is Associate Professor and Chief in the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology at the University of Arkansas for Medical Sciences (UAMS). He recently held the position of Associate Professor of Obstetrics and Gynecology (Ob/Gyn) and served as Vice Chairman on the Institutional Review Board at the University of Southern California. Dr. Burnett also served as a medical advisor for major television network. Dr. Burnett earned his medical degree from Georgetown University in Washington, D.C., where he also completed an internship and residency in Ob/Gyn. He earned an American Cancer Society Clinical Fellowship, as well as a Residence Award in gynecology for his academic performance. He also completed a Gynecologic Oncology Fellowship at Georgetown. He is certified by the Board of Gynecology Oncology. Dr. Burnett is a member of the society of Gynecologic Oncologists. He has contributed to peer reviews, book chapters and other professional publications focusing on cervical cancer and other gynecologic disorders. Dr. Burnett served as the principal investigator for multiple research projects on pharmaceutical comparison studies as well as other alternative treatments for gynepathic carcinoma. He has also had the honor of receiving the UAMS College of Medicine's Red Sash award for Medical Student Teaching in 2009 and has been selected by Best Doctors, Inc. as one of the Best Doctors in America 2007-2009.


    Collapse Research 
    Collapse research activities and funding
    PSC 27469-83     (BURNETT, ALEXANDER)Aug 17, 2010 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 AMENDMENT TO MASTER AGREEMENT
    Role: Principal Investigator
    MK-8669     (BURNETT, ALEXANDER F)Jul 27, 2009
    ARIAD Pharmaceutical
    AP 23573-07-205 A Randomized phase II trial of deforolimus (AP23573; MK-8669) compared to progestin in female adult patients with advanced endometrial
    Role: Principal Investigator
    RC1AI078515     (BURNETT, ALEXANDER FERGUSON)Sep 1, 2007 - Feb 28, 2011
    NIH
    Oral Interleukin 11 as a Countermeasure against Radiation Injury to Gut
    Role: Principal Investigator
    ACRIN/GOG 0262     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    ACRIN/GOG0262     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG 0130F     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG 0225     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG 0240     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG 0244     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG 0252     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG 0269     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG0130F     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG0225     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG0240     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG0244     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG0252     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    GOG0269     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    NSC# 710428     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    NSC#710428     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    PSC27469     (BURNETT, ALEXANDER F)Jul 24, 2007 - Mar 31, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Oklahoma Health Sciences Center
    OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE
    Role: Principal Investigator
    CSA FDI-03     (BURNETT, ALEXANDER)Oct 13, 2006 - Oct 15, 2007
    Fujirebio Diagnostics, Inc
    Evaluation of Multiple Biomarker Assays to Estimate Risk of Ovarian Cancer in Patients Presenting with a Pelvic Mass
    Role: Principal Investigator
    CSAFDI     (BURNETT, ALEXANDER F)Oct 13, 2006 - Oct 15, 2007
    Fujirebio Diagnostics, Inc
    Evaluation of Multiple Biomarker Assays to Estimate Risk of Ovarian Cancer in Patients Presenting with a Pelvic Mass
    Role: Principal Investigator
    EPONRP2001     (BURNETT, ALEXANDER F)Jun 28, 2006 - Jun 28, 2009
    Ortho Biotech Products, L.P.
    A Randomized, Double-Blind, PlaceboControlled, Multicenter, 18 Week Pilot Study to Investigate the Neuroprotective Effect of Procrit® (Epoetin Alfa) o
    Role: Principal Investigator
    29296 SpectRx-Guided Thera CTA     (BURNETT, ALEXANDER F)Nov 1, 2005 - Nov 1, 2008
    Guided Therapeutics
    Spectroscopic Evaluation of Cervical Neoplasia
    Role: Principal Investigator
    29296SpectRx-GuidedTheraCTA     (BURNETT, ALEXANDER F)Nov 1, 2005 - Nov 1, 2008
    Guided Therapeutics
    Spectroscopic Evaluation of Cervical Neoplasia
    Role: Principal Investigator
    RT     (BURNETT, ALEXANDER)Jul 13, 2004 - Jul 13, 2009
    Allos Therapeutics, Inc.
    2004-27: A Phase I / II Study to Evaluate the Safety, Tolerance, and Efficacy of RSR13 (efaproxiral) Administered to Patients Receiving a Course of Ci
    Role: Principal Investigator
    RT-012 CTA     (BURNETT, ALEXANDER)Jul 13, 2004 - Jul 13, 2009
    Allos Therapeutics, Inc.
    2004-27: A Phase I / II Study to Evaluate the Safety, Tolerance, and Efficacy of RSR13 (efaproxiral) Administered to Patients Receiving a Course of Ci
    Role: Principal Investigator
    B9E-US-S302     (BURNETT, ALEXANDER F)Oct 30, 2003 - Oct 30, 2006
    Lilly Research Laboratories
    Protocol B9E-US-S302, Phase III Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by Paclitaxel Consolidation versu
    Role: Principal Investigator
    PRN 13503 B9E-US-S302 CSAA     (BURNETT, ALEXANDER F)Oct 30, 2003 - Oct 30, 2006
    Lilly Research Laboratories
    Protocol B9E-US-S302, Phase III Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by Paclitaxel Consolidation versu
    Role: Principal Investigator
    PRN13503B9E-US-S302CSAA     (BURNETT, ALEXANDER F)Oct 30, 2003 - Oct 30, 2006
    Lilly Research Laboratories
    Protocol B9E-US-S302, Phase III Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by Paclitaxel Consolidation versu
    Role: Principal Investigator
    MK     (RAJ, VIVEK)Aug 6, 1999 - Mar 29, 2007
    Merck & Company, Inc.
    A Multicenter Randomized, Parallel-Group, Placebo-controlled, Double-Blind Study with In-house Blinding to Determine the Effect of 156 Weeks of Treatm
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Burnett AF, Pitman TC, Baekelandt JF. vNOTES (vaginal natural orifice transluminal surgery) gynecologic procedures in morbidly and super-morbidly obese women: five year experience. Arch Gynecol Obstet. 2024 02; 309(2):565-570. PMID: 37880384.
      View in: PubMed
    2. Baekelandt J, Chuang L, Zepeda Ortega JH, Burnett A. A new approach to radical hysterectomy: First report of treatment via vNOTES for cervical cancer. Asian J Surg. 2023 04; 46(4):1852-1853. PMID: 36319544.
      View in: PubMed
    3. Prabhu AV, Schad MD, Burnett AF, Lewis GD. Radiation treatment for refractory endometriosis: a 38-year-old female presenting with vaginal bleeding. Rep Pract Oncol Radiother. 2021; 26(3):457-462. PMID: 34277101.
      View in: PubMed
    4. Pabona JMP, Burnett AF, Brown DM, Quick CM, Simmen FA, Montales MTE, Liu SJ, Rose T, Alhallak I, Siegel ER, Simmen RC. Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells. Reprod Sci. 2020 01; 27(1):267-277. PMID: 32046384.
      View in: PubMed
    5. Hall C, Stone RL, Gehlot A, Zorn KK, Burnett AF. Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence. Int J Gynecol Cancer. 2016 Feb; 26(2):313-7. PMID: 26588235.
      View in: PubMed
    6. Kodell RL, Haun RS, Siegel ER, Zhang C, Trammel AB, Hauer-Jensen M, Burnett AF. Novel Use of Proteomic Profiles in a Convex-Hull Ensemble Classifier to Predict Gynecological Cancer Patients' Susceptibility to Gastrointestinal Mucositis as Side Effect of Radiation Therapy. J Proteomics Bioinform. 2015 Jul; 8(7):149-154. PMID: 26430350.
      View in: PubMed
    7. Biju PG, Gubrij I, Garg S, Gupta PK, Hauer-Jensen M, Burnett AF. Radiation lethality potentiation in total body irradiated mice by a commonly prescribed proton pump inhibitor, Pantoprazole sodium. Int J Radiat Biol. 2014 Jul; 90(7):554-9. PMID: 24646079.
      View in: PubMed
    8. Goyne HE, Stone PJ, Burnett AF, Cannon MJ. Ovarian tumor ascites CD14+ cells suppress dendritic cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase. J Immunother. 2014 Apr; 37(3):163-9. PMID: 24598451.
      View in: PubMed
    9. Burnett AF, Biju PG, Lui H, Hauer-Jensen M. Oral interleukin 11 as a countermeasure to lethal total-body irradiation in a murine model. Radiat Res. 2013 Dec; 180(6):595-602. PMID: 24219324.
      View in: PubMed
    10. Twiggs LB, Chakhtoura NA, Ferris DG, Flowers LC, Winter ML, Sternfeld DR, Lashgari M, Burnett AF, Raab SS, Wilkinson EJ. Multimodal hyperspectroscopy as a triage test for cervical neoplasia: pivotal clinical trial results. Gynecol Oncol. 2013 Jul; 130(1):147-51. PMID: 23591399.
      View in: PubMed
    11. Simmons CD, Pabona JM, Heard ME, Friedman TM, Spataro MT, Godley AL, Simmen FA, Burnett AF, Simmen RC. Kruppel-like factor 9 loss-of-expression in human endometrial carcinoma links altered expression of growth-regulatory genes with aberrant proliferative response to estrogen. Biol Reprod. 2011; 85(2):378-85.
    12. Simmons CD, Pabona JM, Heard ME, Friedman TM, Spataro MT, Godley AL, Simmen FA, Burnett AF, Simmen RC. Kr?ppel-like factor 9 loss-of-expression in human endometrial carcinoma links altered expression of growth-regulatory genes with aberrant proliferative response to estrogen. Biol Reprod. 2011 Aug; 85(2):378-85. PMID: 21543766.
      View in: PubMed
    13. Burnett AF, Stone PJ, Klimberg SV, Gregory JL, Roman JR. Lower extremity glandography (LEG): a new concept to identify and enhance lymphatic preservation. Int J Gynecol Cancer. 2011 Apr; 21(3):582-6. PMID: 21436707.
      View in: PubMed
    14. Stone P, Burnett A, Burton B, Roman J. Overcoming extreme obesity with robotic surgery. Int J Med Robot. 2010 Dec; 6(4):382-5. PMID: 20812220.
      View in: PubMed
    15. A. Brockmeyer, A. Burnett, L. Roman, A F Burnett, S. Goshen, L. Muderspach, A. Yessaian, C. Morrow, H. Pham. Phase I/II study of concurrent continuous-infusion topotecan with pelvic radiotherapy for locally advanced cervical carcinoma. 2010; (0090-8258):529.
    16. Burnett AF, Stone PJ, Duckworth LA, Roman JJ. Robotic radical trachelectomy for preservation of fertility in early cervical cancer: case series and description of technique. J Minim Invasive Gynecol. 2009 Sep-Oct; 16(5):569-72. PMID: 19835799.
      View in: PubMed
    17. Burnett, A.F., Stone, P.J., Duckworth, L., Roman, J. J. Robotic Radical Trachelectomy for Preservation of Ferrtility in Early Cervical Cancer. J Minim Invasive Gynecol. 2009; 16(5):569-72.
    18. Boerma M, Wang J, Burnett AF, Santin AD, Roman JJ, Hauer-Jensen M. Local administration of interleukin-11 ameliorates intestinal radiation injury in rats. Cancer Res. 2007 Oct 01; 67(19):9501-6. PMID: 17909060.
      View in: PubMed
    19. Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol. 2007 Aug; 110(2 Pt 2):518-20. PMID: 17666649.
      View in: PubMed
    20. Santin AD, Bellone S, Siegel ER, McKenney JK, Thomas M, Roman JJ, Burnett A, Tognon G, Bandiera E, Pecorelli S. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. Clin Cancer Res. 2007 Jun 01; 13(11):3339-46. PMID: 17545541.
      View in: PubMed
    21. Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, Roman JJ, Burnett AF, Pecorelli S, Santin AD. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecol Oncol. 2007 Sep; 106(3):513-20. PMID: 17540437.
      View in: PubMed
    22. Lowe MP, Bahador A, Muderspach LI, Burnett A, Santos L, Caffrey A, Roman LD, Morrow CP. Feasibility of laparoscopic extraperitoneal surgical staging for locally advanced cervical carcinoma in a gynecologic oncology fellowship training program. J Minim Invasive Gynecol. 2006 Sep-Oct; 13(5):391-7. PMID: 16962520.
      View in: PubMed
    23. Santin AD, Diamandis EP, Bellone S, Marizzoni M, Bandiera E, Palmieri M, Papasakelariou C, Katsaros D, Burnett A, Pecorelli S. Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. Am J Obstet Gynecol. 2006 May; 194(5):1296-302. PMID: 16647913.
      View in: PubMed
    24. Burnett AF. Radical trachelectomy with laparoscopic lymphadenectomy: review of oncologic and obstetrical outcomes. Curr Opin Obstet Gynecol. 2006 Feb; 18(1):8-13. PMID: 16493253.
      View in: PubMed
    25. Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. Gynecol Oncol. 2006 Mar; 100(3):469-78. PMID: 16249018.
      View in: PubMed
    26. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005 Oct 01; 104(7):1391-7. PMID: 16116605.
      View in: PubMed
    27. Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005 Jul; 98(1):24-30. PMID: 15894362.
      View in: PubMed
    28. Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S, Santin AD. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol. 2005 Jul; 98(1):92-8. PMID: 15904949.
      View in: PubMed
    29. Santin AD, Can? S, Bellone S, Palmieri M, Siegel ER, Thomas M, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res. 2005 May 15; 65(10):4334-42. PMID: 15899825.
      View in: PubMed
    30. Santin AD, Diamandis EP, Bellone S, Soosaipillai A, Cane S, Palmieri M, Burnett A, Roman JJ, Pecorelli S. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer. Clin Cancer Res. 2005 May 01; 11(9):3320-5. PMID: 15867230.
      View in: PubMed
    31. Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, Kay HH, Roman JJ, Burnett A, Pecorelli S. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005 Mar; 192(3):813-8. PMID: 15746676.
      View in: PubMed
    32. Santin AD, Zhan F, Bignotti E, Siegel ER, Can? S, Bellone S, Palmieri M, Anfossi S, Thomas M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Pecorelli S. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005 Jan 20; 331(2):269-91. PMID: 15629771.
      View in: PubMed
    33. Garcia AA, Roman L, Muderspach L, O'meara A, Facio G, Edwards S, Burnett A. Phase I clinical trial of topotecan and pegylated liposomal doxorubicin. Cancer Invest. 2005; 23(8):665-70. PMID: 16377584.
      View in: PubMed
    34. Santin AD, Bellone S, Roman JJ, Burnett A, Cannon MJ, Pecorelli S. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy. Curr Pharm Des. 2005; 11(27):3485-500. PMID: 16248803.
      View in: PubMed
    35. Williams SD, Kauderer J, Burnett AF, Lentz SS, Aghajanian C, Armstrong DK. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group. Gynecol Oncol. 2004 Dec; 95(3):496-9. PMID: 15581952.
      View in: PubMed
    36. Burnett AF, O'Meara AT, Bahador A, Roman LD, Morrow CP. Extraperitoneal laparoscopic lymph node staging: the University of Southern California experience. Gynecol Oncol. 2004 Oct; 95(1):189-92. PMID: 15385130.
      View in: PubMed
    37. Burnett AF, Bahador A, Amezcua C. Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy. Gynecol Oncol. 2004 Sep; 94(3):832-4. PMID: 15350383.
      View in: PubMed
    38. Keys HM, Bundy BN, Stehman FB, Okagaki T, Gallup DG, Burnett AF, Rotman MZ, Fowler WC. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol. 2003 Jun; 89(3):343-53. PMID: 12798694.
      View in: PubMed
    39. Burnett AF, Roman LD, O'Meara AT, Morrow CP. Radical vaginal trachelectomy and pelvic lymphadenectomy for preservation of fertility in early cervical carcinoma. Gynecol Oncol. 2003 Mar; 88(3):419-23. PMID: 12648596.
      View in: PubMed
    Burnett's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (194) concept(s)
    _
    Co-Authors Expand Description
    See all (6) people
    _
    Similar People Expand Description
    See all (31) people
    _
    Same Department Expand Description
    Search Department